Safe CRISPR: Challenges and Possible Solutions.

Applications of CRISPR in human health and in gene drives are at the forefront of biological research as tools. This technology will affect humankind and our environment, so as this technology pushes forward, the design and implementation of safety measures is imperative. Novel technologies and forethought in various applications of CRISPR are essential for using this technology safely. Here, we review environmental and health-related safety concerns associated with using CRISPR and ways proposed to minimize risk.

[1]  A. Lewis,et al.  CRISPR-Cas9 and the Non-Germline Non-Controversy , 2016 .

[2]  Y. Suh,et al.  In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease , 2017, F1000Research.

[3]  David Cyranoski,et al.  Chinese scientists to pioneer first human CRISPR trial , 2016, Nature.

[4]  Christophe Boëte,et al.  Agricultural pest control with CRISPR‐based gene drive: time for public debate , 2017, EMBO reports.

[5]  Andrew G. Clark,et al.  Reducing resistance allele formation in CRISPR gene drive , 2018, Proceedings of the National Academy of Sciences.

[6]  Xiujun Zhang,et al.  A chemical-inducible CRISPR-Cas9 system for rapid control of genome editing. , 2016, Nature chemical biology.

[7]  Devora Najjar,et al.  Daisy quorum drives for the genetic restoration of wild populations , 2017, bioRxiv.

[8]  Martin A. Nowak,et al.  Daisy-chain gene drives for the alteration of local populations , 2016 .

[9]  Jia Luo,et al.  Genome-wide identification of CRISPR/Cas9 off-targets in human genome , 2014, Cell Research.

[10]  Alan R. Davidson,et al.  Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system , 2012, Nature.

[11]  J. Keith Joung,et al.  Efficient Delivery of Genome-Editing Proteins In Vitro and In Vivo , 2014, Nature Biotechnology.

[12]  James E. DiCarlo,et al.  Safeguarding CRISPR-Cas9 gene drives in yeast , 2015, Nature Biotechnology.

[13]  M. Gonçalves,et al.  In trans paired nicking triggers seamless genome editing without double-stranded DNA cutting , 2017, Nature Communications.

[14]  Demetrios A. Spandidos,et al.  Role of the CRISPR system in controlling gene transcription and monitoring cell fate , 2017, Molecular medicine reports.

[15]  Sara Reardon,et al.  First CRISPR clinical trial gets green light from US panel , 2016, Nature.

[16]  D. Patel,et al.  Type V CRISPR-Cas Cpf1 endonuclease employs a unique mechanism for crRNA-mediated target DNA recognition , 2016, Cell Research.

[17]  Austin Burt,et al.  Site-specific selfish genes as tools for the control and genetic engineering of natural populations , 2003, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[18]  Samuel H Sternberg,et al.  Rational design of a split-Cas9 enzyme complex , 2015, Proceedings of the National Academy of Sciences.

[19]  M. Bonsall,et al.  Interplay of population genetics and dynamics in the genetic control of mosquitoes , 2014, Journal of The Royal Society Interface.

[20]  G. Church,et al.  Cas9 gRNA engineering for genome editing, activation and repression , 2015, Nature Methods.

[21]  David R. Liu,et al.  In vivo base editing of post-mitotic sensory cells , 2018, Nature Communications.

[22]  W. Harrington,et al.  A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. , 2018, Cell reports.

[23]  David R. Liu,et al.  Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction , 2018, Nature Biotechnology.

[24]  Huatai Xu,et al.  In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR–dCas9-activator transgenic mice , 2018, Nature Neuroscience.

[25]  Chance M. Nowak,et al.  Guide RNA engineering for versatile Cas9 functionality , 2016, Nucleic acids research.

[26]  Dona M. Kanavy,et al.  Developing gene drive technologies to eradicate invasive rodents from islands , 2018 .

[27]  Fred Gould,et al.  Evaluating strategies for reversing CRISPR-Cas9 gene drives , 2017, Scientific Reports.

[28]  Kim Vn.  RNA-targeting CRISPR comes of age , 2018 .

[29]  Tim S Doherty,et al.  Invasive predators and global biodiversity loss , 2016, Proceedings of the National Academy of Sciences.

[30]  J. P. Collins,et al.  A roadmap for gene drives: using institutional analysis and development to frame research needs and governance in a systems context , 2017 .

[31]  Xu Peng,et al.  Publisher Correction: Anti-CRISPR proteins encoded by archaeal lytic viruses inhibit subtype I-D immunity , 2018, Nature Microbiology.

[32]  Philipp W. Messer,et al.  Evolution of Resistance Against CRISPR/Cas9 Gene Drive , 2016, Genetics.

[33]  Yongting Wang,et al.  In vivo gene therapy potentials of CRISPR-Cas9 , 2016, Gene Therapy.

[34]  Gregory McAllister,et al.  p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells , 2018, Nature Medicine.

[35]  Hao Yin,et al.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.

[36]  B. Davies,et al.  CRISPR-Cas orthologues and variants: optimizing the repertoire, specificity and delivery of genome engineering tools , 2017, Mammalian Genome.

[37]  George M Church,et al.  Concerning RNA-guided gene drives for the alteration of wild populations , 2014, bioRxiv.

[38]  Jianhui Gong,et al.  Correction of a pathogenic gene mutation in human embryos , 2017, Nature.

[39]  F. Baylis,et al.  First-in-human Phase 1 CRISPR Gene Editing Cancer Trials:Are We Ready? , 2017, Current gene therapy.

[40]  F. Mingozzi,et al.  Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial , 2017, Human gene therapy.

[41]  R. Weiss,et al.  CRISPR transcriptional repression devices and layered circuits in mammalian cells , 2014, Nature Methods.

[42]  James M. Carothers,et al.  Digital logic circuits in yeast with CRISPR-dCas9 NOR gates , 2017, Nature Communications.

[43]  A. Burt,et al.  A CRISPR–Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes , 2018, Nature Biotechnology.

[44]  Kaihong Zhou,et al.  Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing. , 2018, Journal of the American Chemical Society.

[45]  Jordan J. Green,et al.  Exploring the role of polymer structure on intracellular nucleic acid delivery via polymeric nanoparticles. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[46]  D. Cyranoski.  Ethics of embryo editing divides scientists , 2015, Nature.

[47]  Oscar A. Negrete,et al.  RNA-dependent RNA targeting by CRISPR-Cas9 , 2018, eLife.

[48]  A. Shoushtari,et al.  GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma , 2018, Cell reports.

[49]  Charles A. Gersbach,et al.  RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors , 2018, Nature Communications.

[50]  Zhi Xiong,et al.  Structural basis of CRISPR–SpyCas9 inhibition by an anti-CRISPR protein , 2017, Nature.

[51]  Sruthi Mantri,et al.  Identification of Pre-Existing Adaptive Immunity to Cas9 Proteins in Humans , 2018 .

[52]  A. Burt,et al.  Gene drive through a landscape: Reaction-diffusion models of population suppression and elimination by a sex ratio distorter. , 2016, Theoretical population biology.

[53]  Andrea Crisanti,et al.  The creation and selection of mutations resistant to a gene drive over multiple generations in the malaria mosquito , 2017, bioRxiv.

[54]  Jackson Champer,et al.  Cheating evolution: engineering gene drives to manipulate the fate of wild populations , 2016, Nature Reviews Genetics.

[55]  Martin A. Nowak,et al.  Evolutionary dynamics of CRISPR gene drives , 2016, Science Advances.

[56]  Meagan E. Sullender,et al.  Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.

[57]  David A. Scott,et al.  Rationally engineered Cas9 nucleases with improved specificity , 2015, Science.

[58]  Xin Xu,et al.  Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide , 2018, Proceedings of the National Academy of Sciences.

[59]  Andrea Crisanti,et al.  A CRISPR-Cas9 Gene Drive System Targeting Female Reproduction in the Malaria Mosquito vector Anopheles gambiae , 2015, Nature Biotechnology.

[60]  Z. Cai,et al.  Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells , 2014, Nature Communications.

[61]  Michael Z. Lin,et al.  Tunable and reversible drug control of protein production via a self-excising degron , 2015, Nature chemical biology.

[62]  H. Stone,et al.  Spatial gene drives and pushed genetic waves , 2017, Proceedings of the National Academy of Sciences.

[63]  Timothy K Lu,et al.  Engineering Synthetic Gene Circuits in Living Cells with CRISPR Technology. , 2016, Trends in biotechnology.

[64]  J. Barnes,et al.  CRISPR‐based gene drive in agriculture will face technical and governance challenges , 2017, EMBO reports.

[65]  Austin Burt,et al.  Heritable strategies for controlling insect vectors of disease , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[66]  A. Garnier,et al.  Membrane permeabilizing amphiphilic peptide delivers recombinant transcription factor and CRISPR-Cas9/Cpf1 ribonucleoproteins in hard-to-modify cells , 2018, PloS one.

[67]  M. Elhefnawi,et al.  Modified gold nanoparticles for intracellular delivery of anti-liver cancer siRNA. , 2016, International journal of pharmaceutics.

[68]  Yang Yang,et al.  A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice , 2016, Nature Biotechnology.

[69]  F. Crick,et al.  Selfish DNA: the ultimate parasite , 1980, Nature.

[70]  J. Joung,et al.  High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets , 2015, Nature.

[71]  Haiyan Jiang,et al.  Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population , 2018, Molecular therapy. Methods & clinical development.

[72]  Robert Langer,et al.  Degradable Lipid Nanoparticles with Predictable In Vivo siRNA Delivery Activity , 2014, Nature Communications.

[73]  JoungJ. Keith,et al.  Dimeric CRISPR RNA-Guided FokI-dCas9 Nucleases Directed by Truncated gRNAs for Highly Specific Genome Editing , 2015 .

[74]  Yong Fan,et al.  Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing , 2016, Journal of Assisted Reproduction and Genetics.

[75]  A. Clarke,et al.  Responsible innovation in human germline gene editing: Background document to the recommendations of ESHG and ESHRE , 2018, European Journal of Human Genetics.

[76]  D. Threadgill,et al.  The next generation of rodent eradications: Innovative technologies and tools to improve species specificity and increase their feasibility on islands , 2015 .

[77]  Division on Earth.  Gene Drives on the Horizon: Advancing Science, Navigating Uncertainty, and Aligning Research with Public Values , 2016 .

[78]  Jussi Taipale,et al.  CRISPR–Cas9 genome editing induces a p53-mediated DNA damage response , 2018, Nature Medicine.

[79]  Heidi C. Howard,et al.  One small edit for humans, one giant edit for humankind? Points and questions to consider for a responsible way forward for gene editing in humans , 2017, European Journal of Human Genetics.

[80]  N. Gemmell,et al.  Conservation demands safe gene drive , 2017, PLoS biology.

[81]  Ying Sun,et al.  CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes , 2015, Protein & Cell.

[82]  J. Kinney,et al.  Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization , 2017, Nature Communications.

[83]  Alan R. Davidson,et al.  Multiple mechanisms for CRISPR–Cas inhibition by anti-CRISPR proteins , 2015, Nature.

[84]  Yi Zhou,et al.  A CRISPR/Cas9 vector system for tissue-specific gene disruption in zebrafish. , 2015, Developmental cell.

[85]  M. Ohtsuka,et al.  i-GONAD: a robust method for in situ germline genome engineering using CRISPR nucleases , 2018, Genome Biology.

[86]  Yu-Quan Wei,et al.  Challenges in CRISPR/CAS9 Delivery: Potential Roles of Nonviral Vectors. , 2015, Human gene therapy.

[87]  S. Kiani,et al.  Engineered CRISPR Systems for Next Generation Gene Therapies. , 2017, ACS synthetic biology.

[88]  W. Doolittle,et al.  Selfish genes, the phenotype paradigm and genome evolution , 1980, Nature.

[89]  K. Rommelfanger,et al.  Ethical principles for the use of human cellular biotechnologies , 2017, Nature Biotechnology.

[90]  Daniel G. Anderson,et al.  Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo , 2016, Nature Biotechnology.

[91]  C. Gersbach,et al.  A light-inducible CRISPR/Cas9 system for control of endogenous gene activation , 2015, Nature chemical biology.

[92]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[93]  Marina A Dobrovolskaia,et al.  Current understanding of interactions between nanoparticles and the immune system. , 2016, Toxicology and applied pharmacology.

[94]  A. Burt,et al.  The Population Genetics of Using Homing Endonuclease Genes in Vector and Pest Management , 2008, Genetics.

[95]  W. Chew.  Immunity to CRISPR Cas9 and Cas12a therapeutics , 2018, Wiley interdisciplinary reviews. Systems biology and medicine.